448 related articles for article (PubMed ID: 17936844)
1. Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml.
Loeb S; Roehl KA; Nadler RB; Yu X; Catalona WJ
J Urol; 2007 Dec; 178(6):2348-52; discussion 2352-3. PubMed ID: 17936844
[TBL] [Abstract][Full Text] [Related]
2. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
Eggener SE; Roehl KA; Yossepowitch O; Catalona WJ
J Urol; 2006 Oct; 176(4 Pt 1):1399-403. PubMed ID: 16952643
[TBL] [Abstract][Full Text] [Related]
3. Prostate specific antigen velocity threshold for predicting prostate cancer in young men.
Loeb S; Roehl KA; Catalona WJ; Nadler RB
J Urol; 2007 Mar; 177(3):899-902. PubMed ID: 17296371
[TBL] [Abstract][Full Text] [Related]
4. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening.
Moul JW; Sun L; Hotaling JM; Fitzsimons NJ; Polascik TJ; Robertson CN; Dahm P; Anscher MS; Mouraviev V; Pappas PA; Albala DM
J Urol; 2007 Feb; 177(2):499-503; discussion 503-4. PubMed ID: 17222618
[TBL] [Abstract][Full Text] [Related]
5. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
Loeb S; Nadler RB; Roehl KA; Antenor JA; Catalona WJ
J Urol; 2007 May; 177(5):1745-8. PubMed ID: 17437803
[TBL] [Abstract][Full Text] [Related]
6. The association between total prostate specific antigen concentration and prostate specific antigen velocity.
Yu X; Loeb S; Roehl KA; Han M; Catalona WJ
J Urol; 2007 Apr; 177(4):1298-302; discussion 1301-2. PubMed ID: 17382716
[TBL] [Abstract][Full Text] [Related]
7. Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer.
Meeks JJ; Thaxton CS; Loeb S; Roehl KA; Helfand BT; Catalona WJ
J Urol; 2008 Apr; 179(4):1340-3. PubMed ID: 18289590
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
[TBL] [Abstract][Full Text] [Related]
9. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.
Berger AP; Deibl M; Steiner H; Bektic J; Pelzer A; Spranger R; Klocker H; Bartsch G; Horninger W
Prostate; 2005 Aug; 64(3):240-5. PubMed ID: 15712213
[TBL] [Abstract][Full Text] [Related]
11. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
D'Amico AV; Hui-Chen M; Renshaw AA; Sussman B; Roehl KA; Catalona WJ
J Urol; 2006 Dec; 176(6 Pt 2):S11-5. PubMed ID: 17084157
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer.
Punglia RS; Cullen J; McLeod DG; Chen Y; D'Amico AV
Cancer; 2007 Nov; 110(9):1973-8. PubMed ID: 17886252
[TBL] [Abstract][Full Text] [Related]
13. Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?
Loeb S; Yu X; Nadler RB; Roehl KA; Han M; Hawkins SA; Catalona WJ
J Urol; 2007 Jan; 177(1):102-6; discussion 106. PubMed ID: 17162013
[TBL] [Abstract][Full Text] [Related]
14. Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4.0 ng./ml. or less.
Harris CH; Dalkin BL; Martin E; Marx PC; Ahmann FR
J Urol; 1997 May; 157(5):1740-3. PubMed ID: 9112517
[TBL] [Abstract][Full Text] [Related]
15. Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy.
Eggener SE; Roehl KA; Catalona WJ
J Urol; 2005 Aug; 174(2):500-4. PubMed ID: 16006880
[TBL] [Abstract][Full Text] [Related]
16. Use of prostate-specific antigen velocity to follow up patients with isolated high-grade prostatic intraepithelial neoplasia on prostate biopsy.
Loeb S; Roehl KA; Yu X; Han M; Catalona WJ
Urology; 2007 Jan; 69(1):108-12. PubMed ID: 17270629
[TBL] [Abstract][Full Text] [Related]
17. Mass screening for prostate cancer in Korea: a population based study.
Song C; Ahn H; Lee MS; Park J; Kwon TG; Kim HJ; Choi HY;
J Urol; 2008 Nov; 180(5):1949-52; discussion 1952-3. PubMed ID: 18801541
[TBL] [Abstract][Full Text] [Related]
18. Prostate specific antigen density correlates with features of prostate cancer aggressiveness.
Kundu SD; Roehl KA; Yu X; Antenor JA; Suarez BK; Catalona WJ
J Urol; 2007 Feb; 177(2):505-9. PubMed ID: 17222621
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
[TBL] [Abstract][Full Text] [Related]
20. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.
Loeb S; Roehl KA; Antenor JA; Catalona WJ; Suarez BK; Nadler RB
Urology; 2006 Feb; 67(2):316-20. PubMed ID: 16442597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]